Lonza Biologics: Responding to Changing Needs
Biologics contract manufacturing is changing rapidly. To maintain its leading position, Lonza Biologics is adopting a more flexible and responsive approach in its dealmaking.
You may also be interested in...
Uncertainties surrounding the ill-defined notion of biogenerics prompted Switzerland's BioPartners to focus instead on developing improved, patent-protected formulations of biologicals, supported by full Phase III trials. The firm's financial backing, small size, and freedom from the low-cost philosophy hampering traditional generics players have worked in its favor--most recently, helping it win rights to a new formulation of interferon beta.
Patent expiries in Europe on proteins such as EPO and interferon alpha may open up a huge market for cheaper versions of these proteins-one which GeneMedix and others are preparing to tap into. But it's a risky game, since there's still no regulatory process in Europe for approving such products.
Eli Lilly hopes that renewed focus on patient selection and a practical message targeted at a variety of hospital personnel--not just prescribers--can boost disappointing sales of its severe sepsis treatment, Xigris, as it gears up to launch the expensive treatment in the price-conscious and heterogeneous European market.